Range of eligible clients: CDEC talked about the uncertainty in the quantity of people with reasonably critical to critical hemophilia B in Canada qualified for etranacogene dezaparvovec. Medical authorities consulted by CADTH indicated that some sufferers who're labeled as acquiring gentle or moderate disease can have a critical bleeding phenotype